Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial

曲妥珠单抗 医学 曲妥珠单抗 肿瘤科 内科学 中期分析 紫杉烷 危险系数 帕妥珠单抗 临床终点 转移性乳腺癌 不利影响 拉帕蒂尼 随机对照试验 乳腺癌 临床研究阶段 临床试验 置信区间 癌症 酪氨酸激酶 中止 药理学 无进展生存期
作者
Jian Zhang,Quchang Ouyang,Qingyuan Zhang,Huihui Li,Xu Wang,Ying Wang,Yongmei Yin,Shusen Wang,Yuanting Gu,Tao Sun,Jingfen Wang,Xinhong Wu,Fanfan Li,Xi Chen,Man Li,Jin Yang,Hua Yang,Zhengkui Sun,Jianyun Nie,Xiaojia Wang
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:44 (31): 3036-3047
标识
DOI:10.1200/jco-26-00602
摘要

PURPOSE To evaluate the safety and efficacy of the novel human epidermal growth factor receptor 2 (HER2)–directed antibody-drug conjugate, trastuzumab botidotin, for the treatment of HER2-positive unresectable/metastatic breast cancer (BC). METHODS In this phase III, open-label, multicenter trial (ClinicalTrials.gov identifier: NCT06968585 ), conducted at 57 centers in China, adult patients with HER2-positive, unresectable/metastatic BC who had received prior trastuzumab and a taxane were randomly assigned (1:1) to receive trastuzumab botidotin or trastuzumab emtansine. The primary end point was progression-free survival (PFS), assessed by blinded independent central review (BICR), using an intention-to-treat analysis. In a prespecified interim analysis of PFS per BICR, trastuzumab botidotin met the prespecified superiority boundary ( P < .0001). We report here the prespecified final analysis of PFS. RESULTS Between July 18, 2023, and April 26, 2024, 365 patients were randomly assigned to trastuzumab botidotin (n = 182) or trastuzumab emtansine (n = 183). At data cutoff (median follow-up, 14.9 months), trastuzumab botidotin resulted in longer PFS than trastuzumab emtansine (median, 11.1 v 4.4 months; hazard ratio [HR], 0.39 [95% CI, 0.30 to 0.51]; nominal P < .0001). Benefit was consistent across subgroups, including those defined by prior lines of anti-HER2 therapy, prior pertuzumab or anti-HER2 tyrosine kinase inhibitors, and visceral metastases. The objective response rate was 76.9% (95% CI, 70.1 to 82.8) with trastuzumab botidotin and 53.0% (95% CI, 45.5 to 60.4) with trastuzumab emtansine. Overall survival data were immature (medians not reached in either group; HR, 0.62 [95% CI, 0.38 to 1.03]). Grade ≥3 treatment-emergent adverse events occurred in 127 (69.8%) and 116 (63.7%) patients in each group, respectively. Ocular treatment-related adverse events had a high incidence with trastuzumab botidotin; however, with a protocol-defined algorithm, most events generally recovered or resolved. Trastuzumab botidotin treatment had low incidences of pulmonary, hematologic, hepatic, and GI toxicities. CONCLUSION Among patients with HER2-positive advanced BC previously treated with trastuzumab and a taxane, trastuzumab botidotin resulted in significantly longer PFS than trastuzumab emtansine, with a distinct safety profile.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
王森发布了新的文献求助20
1秒前
眼睛大的苹果完成签到,获得积分10
1秒前
斯文败类的应助被安静的幼旋采纳,获得10
1秒前
1秒前
2秒前
XylonYu完成签到,获得积分10
3秒前
zik发布了新的文献求助10
3秒前
111发布了新的文献求助10
3秒前
落酒完成签到 ,获得积分10
4秒前
4秒前
嗯哼哈哈发布了新的文献求助10
6秒前
无限玉米发布了新的文献求助10
6秒前
碧蓝的紫寒完成签到,获得积分10
7秒前
香蕉觅云的应助被小芋圆儿采纳,获得10
7秒前
7秒前
小二郎的应助被Ariel采纳,获得10
8秒前
abbytcc完成签到,获得积分10
8秒前
科研通AI6.3的应助被Code_king采纳,获得10
8秒前
youknowdcf发布了新的文献求助10
8秒前
8秒前
wickedzz完成签到,获得积分0
8秒前
SciGPT的应助被Lia采纳,获得10
8秒前
9秒前
9秒前
亦周发布了新的文献求助10
9秒前
果郭发布了新的文献求助10
11秒前
11秒前
Jasper的应助被白樱恋曲采纳,获得10
14秒前
Liang发布了新的文献求助10
14秒前
16秒前
00hello00发布了新的文献求助10
16秒前
科研通AI6.4的应助被1900采纳,获得10
17秒前
18秒前
dingyushu发布了新的文献求助30
19秒前
王森完成签到,获得积分20
19秒前
19秒前
英吉利25发布了新的文献求助10
19秒前
yyy完成签到,获得积分20
20秒前
tangsizhe完成签到,获得积分10
20秒前
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177667
求助须知:如何正确求助?哪些是违规求助? 9568537
关于积分的说明 21799700
捐赠科研通 7772307
什么是DOI,文献DOI怎么找? 3432429
关于科研通互助平台的介绍 2556651
邀请新用户注册赠送积分活动 2478011